JPPT: NEW ASSOCIATE EDITORS
Michael Christensen, PharmD, BCNSP, FPPA
Dr. Christensen received his BScPharm from North Dakota State (‘78) and PharmD from the University of Tennessee (‘82). He completed a residency in pediatric pharmacotherapy at LeBonheur Children's Medical Center and a fellowship in pharmacokinetics and pharmacodynamics at St. Jude Children's Research Hospital. Dr. Christensen spent 6 years at St. Jude Children's Research Hospital as a clinical pharmacist where he developed their metabolic support service. In 1990, Dr. Christensen joined the full-time faculty at the University of Tennessee, College of Pharmacy. Dr. Christensen is a board-certified nutrition support pharmacist since 1993 and currently serves as the Chair for Board of Pharmaceutical Specialties Specialty Council on Nutrition Support Pharmacy. He was the Co-Director for the Pediatric Pharmacology Research Unit funded by the NIH and directed the Children's Foundation Research Institute Pediatric Clinical Research Unit at Le Bonheur Hospital until 2011. Dr. Christensen has more than 130 published articles, book chapters and abstracts. His research interests include the design, implementation and analysis of clinical drug trials in children with an emphasis on early phase or pharmacokinetic disposition studies in children; metabolic and nutrient requirements in infants; and evaluation of prescribing trends for therapeutic areas where a high percentage of pediatric drug development programs failed to result in FDA-approved labeling for use in children.
Michael D. Reed, PharmD, FCCP, FCP
Dr. Michael Reed received his BScPharm (‘75) and PharmD (‘77) degrees from the College of Pharmacy, University of Cincinnati. While obtaining his doctorate he is concurrently a clinical pharmacy/pharmacology residency in pediatrics at the Cincinnati Children's Hospital Medical Center Cincinnati, Ohio.
Dr. Reed's former positions included: Director, Rainbow Clinical Research Center, Rainbow Babies and Children's Hospital, University Hospitals Cleveland Medical Center (2015–2017) and Professor of Pediatrics, School of Medicine, Case Western Reserve University; Director, Rebecca D. Considine Research Institute and Director of the Division of Clinical Pharmacology and Toxicology, Children's Hospital Medical Center of Akron (CHMCA) (2007–2016); Professor and Associate Chair, Department of Pediatrics, Northeastern Ohio Medical University (CHMCA-NEOMED) (2007–2016). Prior to 2007, Dr. Reed held clinical and faculty positions in the department of pediatrics at the Schools of Medicine at Case Western Reserve University and The University of Virginia.
Dr. Reed's research interests focused on the developmental pharmacology and toxicology of drugs in humans and how these data translated into the design of optimal dosing regimens for use in neonates, infants, children, and adults. He has extensive research experience in the design, implementation, and analysis of pharmacokinetic, pharmacodynamic and pharmacogenomic interrelationships as they relate to the maturing infant, child and adolescent. Dr. Reed has received numerous awards, served on numerous governmental (e.g., NIH, FDA) and scholarly committees, served as an officer for academic organizations and has authored more than 250 published works describing his original research activities, invited reviews and book chapters.
Dr. Reed is currently Professor Emeritus of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, Ohio. He is also a principal in Academic Consultants, LLC, a clinical pharmacology and toxicology and drug development consulting company; and is a partner in CPE Consultants, LLC a continuing professional education company.
PPA: NEW OFFICERS
Kristin Klein, PharmD, BCPPS, FPPA
Dr. Kristin Klein has been chosen by members of the Pediatric Pharmacy Association (PPA) as president-elect.
Dr. Klein is a clinical professor at the University of Michigan College of Pharmacy, and is a pediatric infectious diseases clinical pharmacist specialist at Michigan Medicine. Dr. Klein received her BScPharm from Southwestern Oklahoma State University, and her PharmD from the University of Oklahoma. She then completed a specialty residency in pediatric pharmacotherapy at the University of the Sciences in Philadelphia. Dr. Klein is especially interested in training future pharmacists. She spent four years serving on the Michigan Medicine pharmacy residency advisory committee, including two years as the committee's co-chair. She was also the advisor for UM's APhA-ASP chapter for 13 years.
For nearly 20 years, Dr. Klein has been an active member of PPA where she served as co-chair of the Advocacy Committee from 2009 to 2014, and section editor for PPA's Advanced Pediatric Therapeutics textbook. Dr. Klein has been PPA's infectious diseases section leader for the BCPPS BoardPrep course since 2013, and she served as the Infectious Diseases Chair for PPA's 2017 fall meeting. Dr. Klein also served on the PPA Board of Directors for three years (2015–2018). Dr. Klein was inducted as a fellow of PPA in 2012 and achieved board certification in pediatric pharmacy (BCPPS) in 2016.
Dr. Klein will serve as president-elect for 2020–2021, at which time she will transition to PPA president for 2021–2022. During her tenure as president of PPA, Dr. Klein would like to engage the organization in advocating for changes is state pharmacy practice acts to allow pharmacists to immunize children, where it is not currently standard practice.
M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN
Dr. Cober attended the University of Tennessee, College of Pharmacy in Memphis, Tennessee. She completed her PGY1 Pharmacy Residency at Penn State Milton S. Hershey Medical Center in Hershey, Pennsylvania, and her PGY2 Pharmacy Residency in Pediatrics at the University of Michigan Hospitals and Health System in Ann Arbor, Michigan. She is currently the Clinical Coordinator - Neonatal Intensive Care Unit and PGY1 Residency Program Director at Akron Children's Hospital where she provides clinical services and precepts pharmacy students, PGY1 pharmacy residents, and PGY3 medical pediatric residents. She is also the Section Lead for Specialty Care and an Associate Professor in the Department of Pharmacy Practice at Northeast Ohio Medical University (NEOMED). Her didactic teaching is in the areas of pediatrics, women's health, and nutrition. Dr. Cober's expertise is in pediatric pharmacotherapy, nutrition, ethanol lock therapy, and management of patients with intestinal failure.
Dr. Cober served as the Chair of the Webinar Education Committee from 2017–2019 and is the current Chair of the Education Committee. She is active in the Academia, GI/Nutrition, Neonatology, and Residency Program Directors SIGs.
Jeremy Stultz, PharmD
Dr. Stultz is an assistant professor at the University of Tennessee Health Science Center and practices as an Antimicrobial Stewardship Pharmacist at Le Bonheur Children's Hospital in Memphis, TN. He received a PharmD from the University of Pittsburgh School of Pharmacy and completed a PGY-1 Residency at Le Bonheur Hospital and a 2-year Pediatric Pharmacotherapy Fellowship at The Ohio State University and Nationwide Children's Hospital in Columbus, Ohio. He was a faculty member at the Virginia Commonwealth University School of Pharmacy before returning to the University of Tennessee. He has authored over 20 peer-reviewed journal publications focused primarily on pediatric infectious diseases, computerized clinical decision support, and medication safety.
Dr. Stultz attended his first PPA Annual Meeting as a student. Since that time, he has presented multiple times PPA meetings. Dr. Stultz has served as PPA Research Committee Chair, and helped form the Pediatric Pharmacy Association Practice Based Research Network.
DEA DESCHEDULED EPIDIOLEX
The antiepileptic cannabidiol (CBD) oral solution (Epidiolex; GW Pharmaceuticals, Carlsbad, CA) was initially placed in Schedule V of the Controlled Substances Act (CSA). The company filed a post-approval supplement with the FDA to remove the Schedule V designation and the US Drug Enforcement Administration (DEA) has descheduled Epidiolex, making it no longer subject to the CSA. This change is effective immediately and means that all federal controlled-substance restriction have been removed for the product. All prescriptions for CBD oral solution will now be valid for 1 year and can be easily transferred between pharmacies. Additionally, these changes will enable physician to prescribe the medicine free of the requirements of state prescription drug monitoring programs.